198 related articles for article (PubMed ID: 30196795)
21. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
22. Biphenotypic extramedullary blast crisis with MLL gene rearrangement in a case of chronic myeloid leukemia following Dasatinib therapy: An unusual case.
Juneja R; Dhamija G; Dadu T; Handoo A
Indian J Pathol Microbiol; 2016; 59(2):259-60. PubMed ID: 27166066
[No Abstract] [Full Text] [Related]
23. PTHrP-mediated hypercalcaemia in a case of CML blast crisis.
Kubonishi I; Asahi Y; Machida H; Uemura Y; Hatakeyama N; Kubota T; Ohtsuki Y; Miyoshi I
Br J Haematol; 1997 Jan; 96(1):165-7. PubMed ID: 9012703
[TBL] [Abstract][Full Text] [Related]
24. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
25. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Rea D; Legros L; Raffoux E; Thomas X; Turlure P; Maury S; Dupriez B; Pigneux A; Choufi B; Reman O; Stéphane D; Royer B; Vigier M; Ojeda-Uribe M; Recher C; Dombret H; Huguet F; Rousselot P; ;
Leukemia; 2006 Mar; 20(3):400-3. PubMed ID: 16437142
[TBL] [Abstract][Full Text] [Related]
26. Subdural hematomas during CML therapy with imatinib mesylate.
Song KW; Rifkind J; Al-Beirouti B; Yee K; McCrae J; Messner HA; Keating A; Lipton JH
Leuk Lymphoma; 2004 Aug; 45(8):1633-6. PubMed ID: 15370217
[TBL] [Abstract][Full Text] [Related]
27. Extensive bone marrow necrosis and symptomatic hypercalcemia in B cell blastic transformation of chronic myeloid leukemia: report of a case and review of the literature.
Noguchi M; Oshimi K
Acta Haematol; 2007; 118(2):111-6. PubMed ID: 17641550
[TBL] [Abstract][Full Text] [Related]
28. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
30. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
Fang B; Li N; Song Y; Han Q; Zhao RC
Ann Hematol; 2010 Nov; 89(11):1099-105. PubMed ID: 20499235
[TBL] [Abstract][Full Text] [Related]
31. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
32. [Reversion to chronic phase of chronic myelogenous leukemia in blast crisis with small-dose daunorubicin and oral prednisolone].
Kuyama J; Take H
Rinsho Ketsueki; 1995 Dec; 36(12):1353-8. PubMed ID: 8587171
[TBL] [Abstract][Full Text] [Related]
33. Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
Leis JF; Primack SL; Schubach SE; Curtin PT; Druker BJ; Maziarz RT
Haematologica; 2004 Sep; 89(9):ECR30. PubMed ID: 15377482
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
Higashi T; Tsukada J; Kato C; Iwashige A; Mizobe T; Machida S; Morimoto H; Ogawa R; Toda Y; Tanaka Y
Am J Hematol; 2004 Jul; 76(3):275-8. PubMed ID: 15224366
[TBL] [Abstract][Full Text] [Related]
35. Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia.
Singh S; Sharma PK
Indian J Pharmacol; 2016; 48(4):458-459. PubMed ID: 27756963
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
[TBL] [Abstract][Full Text] [Related]
39. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
[TBL] [Abstract][Full Text] [Related]
40. Technetium-99m MDP bone scintigraphic findings of hypercalcemia in accelerated phase of chronic myelogenous leukemia.
Kwak HS; Sohn MH; Lim ST; Kwak JY; Yim CY
J Korean Med Sci; 2000 Oct; 15(5):598-600. PubMed ID: 11069001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
